...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Surgical Oncology >The Indications and Efficacy of Conventional Chemotherapy in Primary and Recurrent Sarcoma
【24h】

The Indications and Efficacy of Conventional Chemotherapy in Primary and Recurrent Sarcoma

机译：常规化疗治疗原发性和复发性肉瘤的适应证和疗效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Conventional chemotherapy can have a favorable impact on the natural history of disease for selected patients with primary high-risk bone and soft-tissue sarcomas. In particular, multidrug regimens are integral to the care of patients with the most aggressive histologies, including Ewing sarcoma, osteosarcoma, and non-pleomorphic rhabdomyosarcoma. Appropriately selected patients with high-risk, clinically localized soft-tissue sarcomas may also benefit from histology-tailored adjuvant or neoadjuvant therapy. For patients with recurrent disease, conventional chemotherapy is frequently the most appropriate first-line therapy; active drugs are discussed at length. Several new promising cytotoxic chemotherapeutic agents are currently under development, including aldoxorubicin, TH-302, and trabectedin.
机译：对于选定的原发性高危骨和软组织肉瘤患者，常规化疗可对疾病的自然病程产生有利影响。特别是，多药治疗方案是治疗组织学最具侵袭性患者（包括尤文肉瘤、骨肉瘤和非多形性横纹肌肉瘤）不可或缺的一部分。适当选择的高危临床局限性软组织肉瘤患者也可能受益于组织学定制的辅助或新辅助治疗。对于复发性疾病患者，常规化疗通常是最合适的一线治疗;本文将详细讨论活性药物。目前正在开发几种新的有前途的细胞毒性化疗药物，包括醛柔比星、TH-302 和曲贝替定。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号